Drugs / USISTAPIDE
USISTAPIDE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01041677 | Feb → Oct 2008 | metabolic disease, obesity disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00672386 | Dec 2007 → Sep 2008 | type 2 diabetes mellitus | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2 | NCT00622765 | Nov 2007 → Jun 2008 | metabolic disease, obesity disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | USISTAPIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103860 ↗ |
| Known as | JNJ-16269110 | “A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor...” NCT00672386 ↗3“This study investigates the effectiveness and safety of 12 weeks of treatment with JNJ-16269110 (R256918), in overweight and obese patients.” NCT00622765 ↗ “JNJ-16269110 and R256918 are different names for the same molecule” NCT01041677 ↗ |
| Known as | JNJ-16269110-AAA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103860 ↗ |
| Known as | R256918 | “A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor...” NCT00672386 ↗ |
| Known as | Usistapida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103860 ↗ |
| Action | Inhibit | “MTP Inhibitor JNJ-16269110 (R256918)” NCT00672386 ↗ |
| Modality | Small molecule | — CHEMBL2103860 ↗ |
| Route | Oral | “5 mg capsules, 10 mg capsules, 15 mg capsules, or matching placebo capsules taken orally.” NCT00622765 ↗ |